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Upper and Lower Gastrointestinal Endoscopic Findings 
in HIV-Infected Patients in the Era of Highly Active 
Antiretroviral Therapy
Russell Parvina, Sindhura Kollia, c, Jamil Shaha, Manan Jhaverib, 
 Madhavi Reddya
Abstract
Background: Endoscopic evaluation with biopsies are instrumental 
in the diagnosis and management of gastrointestinal (GI) disorders 
in the setting of human immunodeficiency virus (HIV) or acquired 
immunodeficiency syndrome (AIDS), especially in the era of highly 
active antiretroviral therapy (HAART).
Methods: A retrospective chart review of 304 HIV-positive and 199 
HIV-negative patients who had undergone upper and/or lower endos-
copy in an urban community hospital from the years 2012 - 2017 was 
performed. Inclusion criteria included men and women between the 
ages of 45 to 75 years, which had undergone colonoscopies between 
within 2012 - 2017 and had tested positive for HIV. They were select-
ed from that population if they had complete charts that included in-
formation regarding symptoms, viral load, cluster of differentiation 4 
(CD4) count, prescribed HAART medication, findings from the upper 
and lower colonoscopy both from the gastroenterologist’s report and 
pathologist’s report. Only then would they be added to the pool of fi-
nal selection that we could compute data from and draw conclusions.
Results: Among HIV patients, those with less than 200 CD4 cells/
µL counts had lower rates of diverticulosis and hemorrhoids, as com-
pared with those with greater than 200 cells/µL counts. Other gross 
and histological findings (from either upper or lower endoscopy) were 
not statistically different between these two groups. In HIV-positive 
patients, gastritis, Helicobacter pylori (HP) infection, and esophagitis 
were significantly less common, while Candida esophagitis was more 
common. Among HIV patients taking different HAART regimens, the 
prevalence of peptic ulcers was significantly higher in those taking IIs 
than that in those who were not.
Conclusions: Physicians should consider the possibility that the GI 
symptoms in HIV-infected patients on HAART may be due to an 
opportunistic infection, even when the CD4 count is more than 200 
cells/µL and the viral load is low.
Keywords: Endoscopy; Colonoscopy; HIV; HAART; AIDS
Introduction
Gastrointestinal (GI) symptoms and pathology are very com-
mon in patients infected with human immunodeficiency virus 
(HIV), affecting almost half of this population [1]. GI disorders 
and their presentations in setting of HIV or acquired immuno-
deficiency syndrome (AIDS) are varied and often nonspecific, 
and endoscopic evaluation with biopsies are instrumental in 
their diagnosis and management. Possible etiologies of GI 
complaints in HIV disease may include the HIV itself, oppor-
tunistic and non-opportunistic infections, side-effects of medi-
cations, and disease processes unrelated to HIV. The preva-
lence and incidence of many GI disorders in HIV have changed 
dramatically in the era of highly active antiretroviral therapy 
(HAART), particularly with the newer generation of HIV regi-
mens. In this retrospective chart review, we report upper and 
lower GI endoscopic findings in HIV-infected patients in an 
urban, community hospital. We have also examined patterns 
of GI findings in patients with low versus high CD4 counts, as 
well as those taking various regimens of HAART.
Materials and Methods
We performed a retrospective chart review of 304 HIV-posi-
tive and 199 HIV-negative patients who had undergone upper 
and/or lower endoscopy at our hospital over the past 5 years 
(2012 -2017). The patients included for data collection and 
analysis were randomly selected from a larger pool of patients 
who had met inclusion criteria. Inclusion criteria were all non-
pregnant adult patients who had undergone endoscopy at our 
hospital. The study sample was divided into HIV-positive and 
HIV-negative patients. The HIV-positive group was further di-
vided into several categories, including those with CD4 counts 
below 200 cells/µL versus those with CD4 counts of 200 cells/
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µL or higher, and those not taking any HIV-targeted therapy 
versus those on HAART. The patients compliant with HAART 
were further categorized into one of three groups, based on 
the specific HAART regimen they were taking at the time of 
endoscopy: backbone of non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) versus protease inhibitors (PIs) versus in-
tegrase inhibitors (IIs).
Data collected included indications for endoscopy, the en-
doscopic findings, biopsy results, age, sex, and ethnicity, HIV 
status, CD4 count, medications, comorbidities, and social his-
tory such as smoking or alcohol use. The different groups of the 
study were compared with respect to these parameters. Statisti-
cal analyses were performed using Statistical Analysis System 
(SAS) version 10.1 and significant level of P = 0.05 was used.
Results
In a total eligible population of 503 patients, 304 were HIV-
positive and 199 were HIV-negative patients. In this group, 376 
esophagogastroduodenoscopies (EGDs) (of which 126 were for 
HIV-positive patients) and 378 colonoscopies (of which 231 
were for HIV-positive patients) were performed and analyzed. 
Mean ages in the two groups were statistically equivalent (54 
and 53 in the HIV and control groups, respectively; P = 0.1768). 
The HIV group comprised significantly more males (54% vs. 
35%; P = 0.0001), more smokers (29% vs. 11%; P = 0.0001), 
more alcohol users (25% vs. 7%; P = 0.0001), and fewer proton 
pump inhibitor (PPI) users (19% vs. 29%; P = 0.0115).
Overall, the most common indications for EGD were dys-
pepsia (32%), heartburn (18%), dysphagia (10%), and anemia 
(10%). Dyspepsia and heartburn were significantly less com-
mon in HIV patients (10% vs. 29%, P < 0.0001 for heartburn). 
The most common gross findings on EGD were gastric mu-
cosal erythema (64%), hiatal hernia (17%), peptic ulcer (11%), 
and gastric erosions (4%). In HIV patients, gastric erythema 
(45% vs. 93%, P < 0.0001) and hiatal hernia (14% vs. 22%, P = 
0.0108) were significantly less common, and erosions (6% vs. 
0%, P = 0.0003) more common. The most common histologi-
cal findings from EGD were gastritis (63%), Helicobacter py-
lori infection (11%), esophagitis (11%), and duodenitis (8%). 
In HIV patients, gastritis (48% vs. 86%, P < 0.0001) including 
Helicobacter pylori infection (4% vs. 22%, P < 0.0001) were 
significantly less common, while Candida esophagitis (3% vs. 
0%, P = 0.0179) was more common (Table 1).
Overall, the most common indications for colonoscopy 
were screening (46%), bleeding (13%), abdominal pain (7%), 
and anemia (7%). Anemia (6% vs. 11%, P = 0.253) and ab-
dominal pain (5% vs. 11%, P < 0.0001) were significantly less 
common in HIV. The most common gross findings on colon-
oscopy were hemorrhoids (49%), polyps (30%), and diver-
ticulosis (19%). The most common histological findings from 
colonoscopy were hyperplastic polyps (12%), adenomas (6%), 
and mucosal lymphoid aggregates (4%). In HIV, both hyper-
plastic polyps (20% vs. 9%, P = 0.0005) and mucosal lym-
phoid aggregates (6% vs. 0%, P = 0.0003) were more common. 
Adenomas (10% vs. 14%, P = 0.2008) and other histological 
findings were equivalently prevalent between HIV patients 
and controls (Table 2).
Among HIV patients, those with CD4 counts less than 
Table 1.  Endoscopy Indications, Gross Findings, and Histological Findings
HIV-negative (n = 199) HIV-positive (n = 304) P value
Indications/presenting symptoms
  Abdominal pain/dyspepsia 90 (45%) 69 (23%) < 0.0001
  Heartburn 58 (29%) 30 (10%) < 0.0001
  Dysphagia 23 (12%) 26 (9%) 0.2676
  Anemia 23 (12%) 25 (8%) 0.2112
  Variceal screening 1 (0.5%) 24 (8%) < 0.0001
Endoscopic findings
  Gastric erythema 185 (93%) 137 (45%) < 0.0001
  Hiatal hernia 45 (22%) 42 (14%) 0.0108
  Peptic ulcer 26 (13%) 31 (10%) 0.3211
  Erosions 0 (0%) 19 (6%) 0.0003
  White plaques 0 (0%) 12 (4%) 0.0046
Histological findings
  Gastritis 172 (86%) 145 (48%) < 0.0001
  Esophagitis 29 (15%) 29 (10%) 0.0838
  Helicobacter pylori 44 (22%) 12 (4%) < 0.0001
  Duodenitis 24 (12%) 18 (6%) 0.0150
  Gastric polyp 14 (7%) 5 (2%) 0.0019
  Candida esophagitis 0 (0%) 8 (3%) 0.0179
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200 cells/µL had lower rates of diverticulosis (7% vs. 21%; 
P = 0.0402) and hemorrhoids (31% vs. 52%; P = 0.0107), as 
compared with those with CD4 counts greater than 200 cells/
µL. Other gross and histological findings (from either upper or 
lower endoscopy) were statistically equivalent between these 
two groups. Among HIV patients taking different HAART 
regimens, there were no significant differences in endoscopic 
findings, except that the prevalence of peptic ulcers was sig-
nificantly higher in those taking IIs (15%) versus those taking 
NNRTIs (8%) or PIs (7%) (P = 0.0495).
Discussion
HIV/AIDS is a multisystemic disorder that affects virtually 
every organ of the body. The GI system is one of the most 
common organ-systems to be affected by HIV/AIDS, pro-
ducing a wide variety of symptomatic complaints. Given that 
HIV/AIDS is an immunological disorder, infectious etiologies, 
both opportunistic and non-opportunistic, are among the most 
important factors in HIV symptomatology. With the advent 
of HAART, particularly the newer regimens of antiretroviral 
therapy, the incidence and prevalence of various GI infections 
in HIV have changed dramatically.
In our study, mucosal erythema of the upper GI tract and 
histologically defined esophagitis, gastritis, or duodenitis from 
various causes were among the most common findings. Can-
dida esophagitis is the most common esophageal disorder ob-
served in HIV patients [2], with a prevalence of 43-53% in 
the pre-HAART era, and 17-24% since the introduction of 
HAART [2]. In our study, the incidence of Candida esophagitis 
was higher in HIV-positive patients than that of HIV-negative 
patients. Our results were similar to many prior studies, where 
the incidence of Candida esophagitis in HIV-positive patients 
was significantly higher than that of HIV-negative patients [2]. 
Numerous studies further demonstrate that the prevalence of 
Candida is higher in HIV-positive patients with CD4+ count < 
200 cells/µL than those with CD4+ count > 200 cells/µL, and 
higher in those with a greater HIV viral load [2, 3]. Our study 
revealed a 3.0% prevalence of Candida esophagitis, lower than 
previously reported since the introduction of HAART new 
regimens. Our results indicate that the effectiveness of the new 
HAART regimens.
Cytomegalovirus (CMV), herpes simplex virus (HSV), 
and Kaposi’s sarcoma are other important etiologies of es-
ophagitis in HIV patients. CMV esophagitis is characterized 
by symptoms of odynophagia, dysphagia and endoscopic find-
ings of multiple, well-demarcated vertical/horizontal linear 
shallow ulcers, most commonly between the mid-third and 
lower-third areas of the esophagus [4]. HSV is the least com-
mon of the infectious agents that cause esophagitis in HIV-
infected patients. The shallow erosive ulcers are similar to 
erosive reflux esophagitis and have a wider distribution pattern 
than CMV [5]. Kaposi's sarcoma is rarely found in the esopha-
gus, and presents as dysphagia rather than odynophagia [5]. It 
appears as submucosal ulcerations or as linitis plastica in the 
stomach [6]. While Kaposi’s sarcoma lesions in the latter parts 
of the upper GI tract are generally asymptomatic, it has been 
reported to cause acute hemorrhage [6, 7]. Our study did not 
document any cases of CMV/HSV infection or cases of Ka-
posi’s sarcoma or lymphoma, likely due to a relatively small 
sample size and higher CD4 count than that is usually found in 
patients with these disease entities.
As in the general population, infection with Helicobacter 
Table 2.  Colonoscopy Indications, Gross Findings, and Histological Findings
HIV-negative (n = 199) HIV-positive (n = 304) P value
Indications/presenting symptoms
  Screening 85 (43%) 145 (48%) 0.2430
  Gastrointestinal bleeding 24 (12%) 42 (14%) 0.5701
  Anemia 22 (11%) 17 (6%) 0.0253
  Abdominal pain 22 (11%) 14 (5%) < 0.0001
Colonoscopy findings
  Hemorrhoids 96 (48%) 148 (49%) 0.6307
  Colonic polyps 58 (29%) 93 (31%) 0.9617
  Diverticulosis 45 (23%) 53 (17%) 0.1099
  None/normal 4 (2%) 17 (6%) 0.0499
  Colorectal cancer 3 (2%) 8 (3%) 0.3969
Histological findings
  None/normal 96 (48%) 118 (39%) 0.0366
  Hyperplastic polyp 17 (9%) 61 (20%) 0.0005
  Tubular adenoma 27 (14%) 30 (10%) 0.2008
  Mucosal lymphoid aggregates 0 (0%) 19 (6%) 0.0003
  Colitis 9 (5%) 10 (3%) 0.4792
Articles © The authors   |   Journal compilation ©  Gastroenterol Res and Elmer Press Inc™   |   www.gastrores.org98
Endoscopic Findings in HIV Patients  Gastroenterol Res. 2018;11(2):95-99
pylori is an important finding in HIV patients. In our study, 
both Helicobacter pylori and gastroduodenitis of any etiology 
were less common in HIV patients, as compared with con-
trol subjects. These findings are congruent with prior studies, 
where the prevalence of Helicobacter pylori was less in HIV-
positive patients as compared with HIV-negative patients, and 
in those with a CD4 count of < 200 cells/µL than those with 
a CD4 count of > 200 cells/µL [2, 8-11]. These results could 
be the consequence of HIV-positive patients receiving multi-
ple antibiotics therapeutically or prophylactically for typical 
or opportunistic infections, commonly having received eryth-
romycin, amoxicillin or broad spectrum antibiotics [11]. An 
impairment of Helicobacter pylori colonization might also be 
due to progressive atrophic involution of the gastric mucosa 
with secondary hypochlorhydria, representing an unfavorable 
environment [8-10]. Another possibility is that for Helicobac-
ter pylori to persist in a gastric environment, it requires an 
intact mucosal cellular immunity and inflammatory response 
leading to gastritis, which is a response that has been reported 
to be decreased in CD4+ T-cell-deficient individuals [12].
In our study, the most common findings on lower endos-
copy were hemorrhoids, polyps, and diverticulosis with the 
relative prevalence of these findings statistically equivalent be-
tween HIV-positive and HIV-negative patients. On histology, 
however, hyperplastic polyps and mucosal lymphoid aggre-
gates on biopsy samples were more common in HIV-positive 
patients. Kasapovic et al investigated rates of mucosal abnor-
malities detected by screening colonoscopy in 96 HIV-infected 
patients over the age of 50 in Germany, and found that the ad-
enoma detection rate during colorectal cancer (CRC) screen-
ing colonoscopy in HIV-positive patients was higher than that 
seen in the general population in the country [13]. Their data 
showed that adenomas were detected in 26% of all screened 
HIV-positive patients, while published data predict adenoma 
detection rates of 12-20% in the general population [14]. Stud-
ies in the United States such as from Bini et al showed that, 
compared with control subjects, HIV-positive patients were 
significantly less likely to have hyperplastic polyps and were 
significantly more likely to have adenomas 6 - 9 mm in di-
ameter [15]. Advanced neoplastic lesions and colorectal ad-
enocarcinomas were more common in HIV-positive patients, 
although these differences did not reach statistical significance 
[15]. In our study, the relative prevalence of colonic polyps 
on endoscopy was statistically equivalent between our HIV-
positive and HIV-negative patients, possibly because the sta-
tistical power may not have been strong enough to detect a dif-
ference. Alternatively, the study population in our study may 
be different as we included patients undergoing colonoscopy 
for screening (48%) as well as for other indications such as GI 
symptoms (52%).
One hospital-based cross-sectional study in Cameroon 
was undertaken in order to determine the prevalence and de-
terminants of anorectal pathology in 390 HIV-infected patients 
who visited a hospital HIV treatment center [16]. The median 
duration since HIV diagnosis was 3 years and the median CD4 
count was 411 cells/µL [16]. The prevalence of anorectal pa-
thology was 22.8% [16]. Hemorrhoids and proctitis were the 
most common lesions found; each was discovered in 10% re-
spectively [16]. In our study, hemorrhoids were the most com-
mon findings on colonoscopy in both the HIV-positive cohort 
and the HIV-negative cohort.
After the widespread use of HAART, several studies 
showed changes in the incidence of AIDS-defining and non-
AIDS-defining malignancies among HIV/AIDS patients. One 
systematic review of 21 observational studies, involving more 
than 600,000 HIV-positive individuals and 10,891 new cases 
of malignancies, evaluated the incidence of cancers before and 
after the introduction of HAART [17]. After introduction of 
HAART, the incidence of AIDS-defining cancers (e.g., Kapo-
si’s sarcoma and non-Hodgkin’s lymphoma) decreased signifi-
cantly, as HAART decreased the patient’s total HIV burden, 
maintained immune system function, and prevented opportun-
istic infections that previously led to death [17]. The incidence 
of several non-AIDS-defining cancers increased after the early 
use of HAART, likely due to the increased survival made pos-
sible by the new antiretroviral drugs [17]. In our study, the 
rates of colorectal cancer were statistically equivalent between 
the HIV-positive and HIV-negative groups. Interestingly, 
studies that have compared pre- and post-HAART eras have 
demonstrated, on a consistent basis, an alarming increase in 
the incidence of invasive anal cancer during the HAART era 
[18]. The reasons for this development are likely multifacto-
rial. There are several theories but further research is needed to 
explain this finding.
Our study findings yielded low rates of colitis or specific 
colonic infectious agents, possibly due to small sample sizes. 
However, lower GI infections certainly are important entities 
in GI disorders in the setting of HIV. Since the introduction 
of HAART, the incidence of opportunistic infections has de-
creased significantly, but has not disappeared. In fact, in large 
inner-city hospitals, where there are often more HIV-infected 
patients, who are either unaware of their HIV status or non-
compliant with their HAART regimens, GI symptoms and 
corresponding endoscopic findings and biopsy results are not 
uncommon [19]. There is a broad spectrum of pathogens and 
opportunistic infections that affect the lower GI tract in HIV/
AIDS. These include bacterial infections (Listeria, Salmonel-
la, Shigella, Mycobacterium avium complex, and spirochetes), 
viral infections (CMV, adenovirus, and herpes simplex), fun-
gal infections (Candida, Cryptococcus, Histoplasma, and mi-
crosporidia), and parasitic infections (Giardia, Isospora, and 
cryptosporidium) [19]. In our study, the etiology of colitis has 
not been further subclassified.
Although the frequency of opportunistic infections in 
HIV-positive individuals with CD4 counts greater than 200 
was low, performing colonoscopy was still useful, especially 
to diagnose CMV infection [20]. Indeed, although the use of 
HAART has led to a decreased incidence of opportunistic in-
fections, the physician should not abandon the possibility that 
the GI symptoms in HIV-infected patients on HAART may be 
due to an opportunistic infection, even when the CD4 count is 
high and the viral load is low [21].
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